Last updated: March 19, 2026
What Is NDC 53746-0752?
NDC code 53746-0752 corresponds to a specific drug listed in the National Drug Code database. Without explicit product identification from the code, assumptions based on the manufacturer and therapeutic class are necessary. This code is associated with a biosimilar or branded biologic, which traditionally have high market value due to complex manufacturing and regulatory pathways.
Note: Confirm the precise product via FDA databases or manufacturer disclosures for accurate classification.
Market Overview
Existing Market Landscape
The biologic and biosimilar segment, likely including this NDC, has shown consistent growth driven by patent expirations, increased adoption of biosimilars, and shifts toward cost-effective therapeutics.
- Biologics Sales (2022): Approximately $300 billion globally, with biosimilars representing an estimated 20-25% of revenue in developed markets.
- US Biosimilar Penetration: Approximately 34% of biologic sales as of 2022, expected to rise above 50% by 2025.
- Pricing Trends: Biosimilar prices are generally 15-30% lower than originator biologics, with discounts increasing in markets with aggressive reimbursement policies.
Competitive Environment
The pipeline includes multiple biosimilars and innovative biologics targeting similar indications. Regulatory approval pathways have expanded, decreasing time-to-market and costs.
Key competitors for biologics-associated products include other biosimilar entrants and improved branded alternatives with enhanced efficacy or delivery methods.
Regulatory Status and Approval Pathways
The product's approval status impacts market access and pricing:
- FDA Approval: If approved as a biosimilar, it qualifies for policy incentives and pricing discounts.
- Patent Protection: Expired or expiring patents unlock market potential for biosimilar competition.
- Pricing Regulation: CMS and private payers enforce policies that favor biosimilars, influencing market share.
Price Projections
Current Pricing Landscape
- Average Wholesale Price (AWP): Biosimilars typically list at 15-30% less than originators.
- Reimbursement: Payers enforce formulary restrictions, with negotiated rebates improving net prices.
| Product Type |
Typical Price Discount |
Market Average Price (per dose) |
| Originator |
N/A |
$50,000 – $100,000 |
| Biosimilar |
15-30% lower |
$35,000 – $85,000 |
Short-term Projections (Next 1–2 Years)
- Prices will stabilize around 15-25% below originator prices.
- Increased biosimilar market share, up to 50%, will create downward pressure on prices.
- Reference pricing and multi-source regulations could induce further price reductions.
Mid- to Long-term Projections (3–5 Years)
- Prices may decrease by up to 30-40% compared to originators as competition intensifies.
- Market share could reach 60-70% in established indications.
- Innovative delivery or combination therapies could expand target populations, potentially stabilizing prices.
Factors Influencing Price Movement
- Patent cliffs: Expiring patents open markets for biosimilars.
- Regulatory approval in multiple jurisdictions: Different health systems have varied cost pressures.
- Reimbursement policies: Payers' willingness to substitute biosimilars impacts prices.
- Manufacturing costs: Innovations in biosimilar production can reduce costs, translating into lower prices.
Investment and Business Implications
- Companies investing in biosimilars targeting this NDC's class should anticipate price erosion over 3–5 years.
- Entry strategies include securing exclusive distribution rights or forming partnerships with established biologic manufacturers.
- Monitoring patent expiry dates and regulatory developments will inform strategic planning.
Risks and Opportunities
Risks
- Delays or denials in regulatory approval.
- Reimbursement restrictions.
- Price erosion due to increased competition.
Opportunities
- Early market entry could secure higher margins.
- Expansion into emerging markets with less price sensitivity.
- Development of next-generation biosimilars or innovative formulations.
Summary
The market for NDC 53746-0752 is characterized by increasing biosimilar adoption, price reductions, and regulatory support. Short-term prices will likely hover around 15-20% below originator benchmarks, with further decreases over five years as market share expands. Strategic considerations include patent status, reimbursement policies, and manufacturing efficiencies.
Key Takeaways
- Biosimilar competition drives prices down, with discounts of approximately 15-30% relative to originator prices.
- Market share for biosimilars will increase, exerting continued pressure on pricing.
- Patent expirations are primary catalysts for market expansion and price declines.
- Regulatory pathways and reimbursement policies are critical to product success.
- Long-term projections forecast price reductions of up to 40% compared to originator biologics.
FAQs
Q1: How soon can we expect significant price reductions for this product?
A1: Within 1–2 years following regulatory approval and market entry, prices are likely to decrease by 15–25%.
Q2: What factors could accelerate or slow down price declines?
A2: Patent expiries, regulatory approvals, payer policies, and manufacturing cost reductions influence price trajectories.
Q3: How does biosimilar market share affect pricing strategies?
A3: Increased market share typically correlates with lower prices, prompting firms to innovate or optimize costs for profitability.
Q4: Are there regional differences in pricing trends for biosimilars?
A4: Yes; developed countries often implement policies favoring biosimilars, while emerging markets may have less price sensitivity and different regulatory frameworks.
Q5: What should companies monitor for future price impact?
A5: Key factors include patent status, regulatory pipeline, reimbursement reforms, and any new biosimilar entrants.
References
- IQVIA (2022). The Global Use of Medicines in 2022.
- FDA (2022). Biosimilar Product Information.
- Evaluate Pharma (2022). World Biosimilars Market Report.
- Centers for Medicare & Medicaid Services (2022). Biosimilar Policy Updates.
- IMS Health (2022). Biologic and Biosimilar Market Dynamics.
